×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Habil Khorakiwala
Habil Khorakiwala
Ads
Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich
Drug maker Wockhardt rallies over 9 percent as White House exempts pharma imports from nations with trade pacts
Wockhardt rises 10% after antibiotic Zaynich, undergoing clinical trials, facilitates in a liver transplant
Wockhardt, Serum Institute to invest and share profit equally from new UK jab plant: Habil Khorakiwala
Wockhardt partners with UK govt for COVID-19 vaccines
Wockhardt antibiotic expected to hit US in FY21, market worth $1.5 bn: Khorakiwala
No scope of US intervention in Indian pharma cos: Wockhardt
USFDA issues warning letter to Wockhardt's Ankleshwar plant
Won't be ethical for pharmas to bring back banned drugs: Expert
CP Pharma under FDA lens, will reply in 3 weeks: Wockhardt Chief
IACC Convention: Pharma & the USFDA jigsaw
Need to speed up process of granting patents: Khorakiwala
R&D tax deduction unlikely to impact Wockhardt: CEO
All 9 USFDA observations will be resolved in 3 months: Wockhardt
Will not do any out-licensing in near-term: Wockhardt
Wockhardt gets USFDA nod to market pain-relieving drug
Wockhardt hopeful of early resolution of USFDA row
Wockhardt hopes to resolve FDA ban on two plants in FY16
Hopeful of US FDA issue getting resolved soon: Wockhardt
Expect US FDA to visit remaining facilities soon: Wockhardt
Meet the Khorakiwalas: Gen-Next promoters of Wockhardt
Biggest Gainers and Losers on India Rich List 2013
Q2 earnings hit by recent regulatory actions: Wockhardt
UK regulator issues import alert on Wockhardt's Waluj plant
Wockhardt says USFDA import alert could impact biz by $100m
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio